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pathway) and genetic progression (e.g., the Fearon-Vogelstein pathway
Fearon and Vogelstein, 1990). Steps in adult tumor pathogenesis was
suggested by Armitage and Doll 60 years ago (Armitage and Doll,
1954), with around 7 steps. The question then for pediatric tumors, is
how do steps occur at such a young age and are there fewer steps?The paper by Cresswell et al. (2016) addresses important issues
in understanding the heterogeneous pathogenetic pathways in Wilms
tumors and also practical questions of how sensitive and speciﬁc is a
tumor biopsy for identifying important genetic changes. Histopatholo-
gists are used to morphological heterogeneity in Wilms tumors, and
so underlying genetic heterogeneity may not be a surprise.
Wilms tumors are one of the more common pediatric solid tumors
and have shown a marked improvement in mortality through reﬁne-
ments in therapy, but tumor relapse and therapy related life-long toxic-
itymeanmore tailored approaches are required. If therapy is going to be
based on the tumor genetics, we need a clear understanding of the path-
ogenetic pathways and the likelihood of identifying key prognostic/
diagnostic information in a tumor biopsy.
The pathogenetic differences between children and adults is hinted
at by the relatively simple cytogenetics of many pediatric tumors
compared to adult cancers, and conﬁrmed in some pediatric tumors
(e.g. rhabdoid) by the few changes identiﬁed by deep sequencing
(Fruhwald et al., 2016). Knudson's two-hit hypothesis explains why
some pediatric tumors have few steps (Knudson, 2001). Wilms tumors
though appear genetically heterogeneous, with some tumors showing
few changes and others showing more changes as the current paper
demonstrates (Cresswell et al., 2016). Wilms tumors also appear to be
driven by similar factors as normal embryo-fetal development, (Willis,
1950; Hohenstein et al., 2015). Recently the importance of noncoding
RNA genetic pathways in some groups of Wilms tumors is being identi-
ﬁed (Walz et al., 2015). This suggests complex pathogenetic pathway
involving epigenetic changes (methylation, histone and chromosome
structure and noncoding RNAs) with failure of differentiation and
gene mutations are required (Hohenstein et al., 2015). Some genetic
changes are not single events but multiple changes occurring
synchronously (chromothripsis) are seen in some pediatric tumors
(Chen et al., 2015).m.2016.05.029.
. This is an open access article underClonal progression in some tumor development is suggested by
morphological progression (e.g., as the colonic adenoma-carcinoma
One point to note is that small round blue cell tumors of childhood
tend to be rapidly proliferative and time should bemeasured by cell cy-
cles, rather than months and years. Morphological evidence of clonal
progression is less clear in most pediatric tumors, but Wilms tumors
with their precursor lesions and focal anaplasia suggest progression.
Darwinian clonal evolutionwillmean the tumor contains genetically
heterogenous populations, until some factor selects one group over an-
other. The conceptual distinction between inherent tumor aggressive-
ness and therapy resistance and prognosis was addressed by Beckwith
(Beckwith et al., 1996) who noted that blastemal predominant Wilms
tumors pre-therapy are generally responsive to chemotherapy, but
present with a higher stage. A resistant component may be a small pro-
portion until selected for, and therefore a prognostic genetic change
may not be identiﬁed by a small biopsy, and this is shown in the current
paper (Cresswell et al., 2016).
Currently we are able to deeply sequence a tumor but we need to
understand what the genetic changes mean. Some changes will be im-
portant drivers of the tumor pathogenesis, others may be important
supportive factors (such as increased Insulin-like Growth Factor
(IGF)2), others such as p53 and possibly 1q gain are associated with
prognosis and response to therapy rather than pathogenesis, yet others
may be passenger changes having no survival effect on the tumor or
they may be of uncertain signiﬁcance. Furthermore, epigenetic changes
appear to be crucial in many pediatric tumors. Some of these changes
(referred to in the current paper Cresswell et al., 2016) are seen in the
surrounding “normal” kidney, which may be the environment which
assists tumor development (e.g., the paracrine effect of IGF2) or reﬂect
a subpopulation that has a pro-oncogenic change but has been induced
to differentiate and lost the ability to progress to a tumor.
This paper by Cresswell et al. (2016) therefore demonstrates that
Wilms tumors should be regarded as a complex, heterogeneous system,
with related subpopulations of tumor cells co-existing. Tumor samples
should also be considered as epidemiological samples of related popula-
tions, and the likelihood of detecting minor populations considered.
This paper (Cresswell et al., 2016) suggests future investigations.
The routine collection of tumor samples pre and post therapy, at relapse
and from metastases (and in time circulating tumor nucleic acids),the CC BY license (http://creativecommons.org/licenses/by/4.0/).
12 Commentaryparticularly from poor responders, needs promotion. Newer techniques
such as singlemolecule sequencingwill allow smaller subpopulations to
be detected and quantiﬁed. Highlighted also in the paper is the use of a
growing range of bioinformatic tools to assist our understanding and
handling of the large data, to reﬁne and personalize management for
these tumors. This paper now adds phylogeny to our understanding of
the group of tumors called Wilms tumor (Cresswell et al., 2016).
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